Fig. 2: Pharmacokinetic profile analysis of trastuzumab-Fc variants and aflibercept-Fc variants. | Experimental & Molecular Medicine

Fig. 2: Pharmacokinetic profile analysis of trastuzumab-Fc variants and aflibercept-Fc variants.

From: An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies

Fig. 2

Serum concentration vs. time profiles for the trastuzumab-Fc variants (5 mg/kg, n = 5) a and aflibercept-Fc variants (4 mg/kg, n = 5) b in hFcRn transgenic mice and trastuzumab-Fc variants (6 mg/kg, n = 2) c in cynomolgus monkeys. Data were presented as the mean values and standard errors.

Back to article page